Objective Some patients with malignant gastric outlet obstruction require combined biliary and gastroduodenal stenting (double stenting). However, biliary stent dysfunction can often disturb biliary route maintenance, thus making the optimal biliary stenting for these patients unclear. The present study was designed to assess the factors associated with the long-term maintenance of biliary drainage routes. Methods The clinical features and long-term outcomes were assessed in patients who underwent double stenting.
Introduction
Because it is an effective and minimally invasive procedure, the palliative placement of self-expandable metallic stents (SEMS) has become an alternative to surgical gastro-enterostomy in patients with malignant gastric outlet obstruction (GOO) (1) (2) (3) . However, from 40-92% of patients with malignant GOO have biliary obstructions, thus requiring combined biliary and gastroduodenal stenting (double stenting) (3) (4) (5) . Few studies to date have assessed the efficacy and feasibility of endoscopic double stenting (6) (7) (8) (9) (10) (11) , Intern Med 55: 2153-2161, 2016 DOI: 10.2169/internalmedicine.55.6410 2154 thus making the optimal type unclear.
Most patients requiring double stenting are in a terminal disease stage, and their general condition is not good. Recent improvements in chemotherapy regimens have lengthened survival in some patients (12) . The goals of stent placement should include the longer maintenance of the initial biliary drainage route and the ease of re-intervention for stent dysfunction. In some patients, however, the biliary and gastroduodenal stents are placed in a crossed position, thereby not allowing sufficient maintenance of the initial biliary drainage route and making re-intervention due to biliary stent dysfunction more difficult.
To assess the effects of stent type on biliary stent dysfunction, patients who successfully underwent endoscopic double stenting by the crossed and non-crossed routes were compared retrospectively. The outcomes determined included the clinical course after double stenting, re-interventions for biliary stent dysfunction, and the duration of maintenance of the initial biliary drainage route. This study aimed to evaluate the factors associated with the long-term maintenance of biliary drainage routes.
Materials and Methods

Patients
The databases of the Aichi Cancer Center Hospital were checked to identify the records of all consecutive patients with biliary obstruction and GOO who underwent endoscopic double stenting from February 2010 to December 2013. All malignancies and biliary and gastroduodenal obstructions were evaluated by standard cross-sectional imaging, including by abdominal ultrasound and computed tomography, before stenting. To accurately estimate the utility of endoscopic double stenting, patients who had undergone either percutaneous transhepatic biliary drainage (PTBD) or surgical resection of the stomach or duodenum, and patients with multiple levels of obstruction in the intestinal tract were excluded. The reason that patients who underwent PTBD were excluded was due to the fact that most had undergone combined internal and external drainage, and it was thus quite difficult to compare them with patients who underwent endoscopic internal drainage. The patients were followed up until death or study termination (March 2014, or 3 months after the last procedure). The study protocol was approved by the ethics committee of Aichi Cancer Center Hospital (2014-1-058). All patients provided their written informed consent before undergoing all procedures.
Equipment and procedures
All biliary and gastroduodenal stenting procedures were performed under endoscopic and fluoroscopic guidance, with the patients sedated with intravenous pethidine hydrochloride and midazolam. Endoscopic transpapillary biliary drainage (EBD) using SEMS has become an established and effective method for the palliation of malignant biliary ob-struction (13) (14) (15) (16) (17) (18) . More recently, endoscopic ultrasoundguided biliary drainage (EUS-BD) was found to be a good alternative to PTBD (19) (20) (21) (22) . Technically, EUS-BD includes EUS-guided choledochoduodenostomy (EUS-CDS) and EUS-guided hepaticogastrostomy (EUS-HGS) (23) (24) (25) .
EBD procedure
All EBDs were performed using the standard methods for endoscopic retrograde cholangiopancreatography. Fully covered SEMSs included WallFlex™ Biliary RX Stents (Boston Scientific Japan, Tokyo, Japan) and Niti-S ComVi™ Stents, with lengths of 6 and 8 cm, respectively, and fully expanded diameters of 10 mm each. Duodenoscopes (TJF-260V or JF-260V; Olympus, Tokyo, Japan), ERCP catheters (Tandem™ XL; Boston Scientific Japan), and biliary guidewires (Jagwire™; Boston Scientific Japan or VisiGlide™; Olympus) were also used. Before stenting, endoscopic sphincterotomy was performed for almost all patients using an endoscopic sphincterotomy knife (CleverCut™; Olympus).
EUS-BD procedure
The detailed methods of EUS-BD have been previously described (23) (24) (25) . For EUS-CDS, fully covered WallFlex Biliary RX Stents (Boston Scientific Japan), with lengths of 4 and 6 cm, respectively, and expanded diameters of 10 mm, were mainly used. For EUS-HGS, fully covered Niti-S biliary stents (Taewoong Medical, Seoul, Korea), with lengths of 10 and 12 cm and fully expanded diameters of 6 mm, were used. In addition, linear echoendoscopes (GF-UCT240 or TGF-UC260J; Olympus), 19-gauge needles for fine-needle aspiration (Sono Tip Pro control ; Medi-Globe GmbH, Rosenheim, Germany or Expect ; Boston Scientific Japan), a needle knife (Zimmon papillotomy knife; Cook Endoscopy, Bloomington, USA), an electrical dilator (Cysto-Gastro-Set; Century Medical, Tokyo, Japan), and biliary guidewires (VisiGlide ; Olympus) were also used during these procedures.
Gastroduodenal stenting procedure
Stenting for GOOs involved the use of uncovered Niti-S™ Pyloric Duodenal D-type stents (Taewoong Medical) and WallFlex™ Duodenal stents (Boston Scientific Japan), with lengths of 6, 8, 10, and 12 cm and fully expanded diameters of 20 or 22 mm. Use of a 10-Fr delivery system enabled through-the-scope stent placement using the TJF-260V, JF-260V, CF-H260AI, and CF-Q240 (Olympus) endoscopes with a working channel diameter of !3.7 mm. When using an ERCP catheter (Tandem XL; Boston Scientific Japan) and biliary guidewire (Jagwire; Boston Scientific Japan or RevoWave-J; Piolax Medical Devices, Kanagawa, Japan), the stent delivery system was inserted over the guidewire through the working channel and then the stent was deployed across the stricture.
Data collection
Because the factors that affect the long-term maintenance of the biliary drainage route were unclear, we studied the following factors associated with successful re-intervention in patients with biliary stent dysfunction: age, sex, tumor diagnosis, site of gastroduodenal stricture, preceding stent, initial biliary drainage, and type of double stenting. Next, to determine the applicability of each factor, we divided the patients into two groups according to each factor and estimated the long-term maintenance of the biliary drainage routes.
Definitions
The patient symptoms were evaluated using the GOO scoring system (GOOSS) (1), which categorizes oral intake into four categories: 0 (none), 1 (liquids only), 2 (soft solids), and 3 (a low-residue or normal diet). Biliary stent dysfunction was defined as cholangitis, obstructive jaundice, and liver dysfunction after endoscopic double stenting. Successful re-intervention was defined as either another stent placement or stent exchange along the initial drainage route, and failed re-intervention was defined as either another stent placement or stent exchange along another route. The time to biliary stent dysfunction was defined as the time from double stenting to dysfunction, but did not include the time before the completion of double stenting. The type of double stenting was defined as separate or crossed type ( Fig. 1 ). Functional success, evaluated 1 week after successful endoscopic double stenting, was defined as improvements in serum liver enzyme levels and/or bilirubin levels in biliary drainage specimens and improvement in the symptoms and oral intake in gastroduodenal stentings. Jaundice and/or cholangitis resulting from stent placement were regarded as functional failure. Early and late complications were defined as those occurring within a few days and later than 14 days after the procedure (26), respectively. Data are presented as n (%) unless otherwise indicated.
Statistical analysis
Parametric data are reported as the means ± standard deviations and nonparametric data as the medians and ranges.
A logistic regression analysis was used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) for successful re-intervention in patients with stent dysfunction. If any cell had a value of 0.0, we added 0.5 to all cells before calculating the OR and CI. Categorical data and results were compared using either the chi-square test or Fisher's exact test, as warranted. Biliary stent patency, survival time, and the duration of the initial biliary route were estimated using the Kaplan-Meier method, with the groups compared using the log-rank or generalized Wilcoxon test, as appropriate. All statistical analyses were performed using the StatMate V software program (ATMS, Tokyo, Japan), with p<0.05 considered to be statistically significant.
Results
Patient characteristics
From February 2010 to December 2013, 50 consecutive patients required biliary and gastroduodenal drainage. All underwent successful endoscopic gastroduodenal stenting, but seven failed endoscopic biliary drainage and underwent PTBD. The clinical data of the remaining 43 patients (Fig. 2) were analyzed; Table 1 shows their baseline demographic and clinical characteristics. Their mean age was 65. 4 9.8 years, pancreatic cancer was the most common etiology (88.4%), and the most frequent sites of biliary and gastroduodenal obstruction were the lower/middle bile duct (95.3%) and the duodenum (97.7%), respectively. Sixteen (37.2%) patients had no oral intake (GOOSS 0). At the time that endoscopic double stenting was completed, 69.8% and 30.2% had undergone the separate type and cross type, respectively. After the procedure, the median survival time of all patients was 59 days. During follow-up, 15 patients experienced biliary stent dysfunction, with eight undergoing successful re-intervention via the initial route (Fig. 2) . Table 2 describes all patients who experienced biliary stent dysfunction. Of the seven patients who underwent reintervention via a route other than the initial route, one was treated with EUS-HGS (this patient had initially undergone the placement of separate type stents), and the others were treated with PTBD. All had difficulties with re-intervention through the initial route. A univariate analysis showed the separate type of double stenting to be a unique predictive factor related to successful biliary re-intervention for stent dysfunction (OR 73.67, 95% CI 2.56-2,119.93) ( Table 3) .
Clinical features of biliary stent dysfunction
All other factors, including the biliary drainage methods, were not found to be significant factors.
Clinical results of endoscopic double stenting
The clinical outcomes after double stenting were compared in the patients who had undergone the placement of separate and cross stents. The functional success rates in these two groups were 93.3% (28/30) and 61.5% (8/13), respectively (p=0.02) ( Table 4 ). Functional failures were only caused by gastroduodenal stenting. Two patients in each group did not show any improvement in oral intake, and five patients who underwent cross type double stenting developed jaundice due to covering of the biliary stents. Eighteen biliary stents (11 transpapillary, 6 CDS, and 1 HGS route) in the separate type group and all biliary stents in the cross type group were inserted before gastroduodenal stenting (60.0% vs. 100.0%, respectively; p=0.008). The assessments of the overall biliary drainage routes showed that transpapillary routes were used in 14 patients (46.7%) in the separate type group and 12 (92.3%) in the cross type group (p=0.01). Although the difference was not significant (p=0.1), more gastroduodenal stents tended to be placed in the second portion of the duodenum. There were no significant between-group differences in the rates of early (<14 days) and late (!14 days) complications. Two patients in the cross type group developed increased bilirubin levels 1 day after the procedure so that the gastroduodenal stent had accelerated jaundice. In one patient in the separate type group, the biliary stent was dislocated 239 days after the procedure, and that patient was successfully treated with EUS-HGS.
Clinical outcomes after double stenting
The median survival times after double stenting were 70 days in the separate type group and 50 days in the cross type group (p=0.71) ( Table 5 ). The median times to biliary stent dysfunction after double stenting, which did not include the patency time before double stenting, were 330 and 298 days, respectively (p=0.048) (Fig. 3) . The stent dysfunction rates were similar in the two groups (p=0.32). The success rates of re-intervention among the patients who experienced biliary stent dysfunction were 88.9% in the separate type group and 0.0% in the cross type group (p=0.001), and none of the six patients treated with PTBD for biliary stent dysfunction had undergone internal stenting. The rates of maintenance of biliary drainage routes after double stenting were 96.7% and 53.8%, respectively (p=0.002).
Discussion
Endoscopic gastroduodenal stent placement, especially regarding through-the-scope type stents, has become an alternative to surgical gastroenterostomy for the palliation of symptomatic malignant GOO. The technical (92.9-100.0%) and clinical (76.9-94.4%) success rates of this procedure are high, and survival after stent placement has been lengthened (median overall survival, 52-99 days) (1, 2, (27) (28) (29) . Additional stent intervention has also been shown to be effective in patients with stent dysfunction, thus enabling oral intake to be safely continued (5) . Although gastroduodenal stenting provides long-term benefits, from 40-92% of the patients with malignant GOO develop biliary obstructions and require double stenting (3) (4) (5) . Endoscopic double stenting is difficult to perform, and the efficacy of biliary stenting remains unclear.
EBD using SEMS has been shown to be effective for malignant biliary obstruction, with many studies showing excellent clinical results (13) (14) (15) (16) (17) (18) . EUS-guided biliary drainage (EUS-BD) has been shown to be both feasible and effective in patients who fail conventional EBD (30) . Previous studies, mainly of EUS-CDS, reported technical and clinical success rates of 94-100% and 89-100%, respectively; a median stent patency duration of 152-187 days; and complication rates of 9-19% (19-22, 31-33) . Many patients experienced long-term survival, with re-interventions providing continued palliation in patients who experience stent dysfunction (24, 32) . Although there is no consensus on the relative superiority of EBD and EUS-BD, these two tech-niques have been considered comparable, thereby allowing a wider range of choices to optimize the biliary drainage route.
Most patients requiring double stenting have terminal stage cancer and their general condition is not good. However, recent improvements in chemotherapy regimens have prolonged the survival of such patients (12) . Maintenance of the initial biliary drainage route can more easily allow reintervention for stent dysfunction.
In assessing the biliary stent dysfunction rates after double stenting, we found that the type of double stenting may be associated with successful biliary re-intervention. The placement of the biliary and gastroduodenal stents in a crossed positionmay complicate re-intervention for biliary stent dysfunction, thus resulting in an inability to maintain the initial biliary drainage route. In comparing cross type and separate type stenting, we found the functional success rate after 1 week to be higher in the latter group. Functional failure of cross type stenting, as well as the failure of biliary re-intervention in this group, was primarily due to biliary stent dysfunction. The median overall survival was not long in these patients, suggesting that most were likely to die before experiencing biliary stent dysfunction. Although the overall rates of biliary stent dysfunction after double stenting in these two groups did not differ significantly, the time to biliary stent dysfunction tended to be shorter in the cross type group, suggesting that the position of two stents affects early stent dysfunction and re-intervention failure.
Double stenting techniques have developed rapidly in recent years, but no study to date has assessed the clinical effects of the type of double stenting. In the cross type group, all biliary stents were placed before gastroduodenal stenting, and almost all biliary drainage routes (92.3%) were transpapillary. Thus, gastroduodenal stricture near the papilla of Vater and in patients already treated with EBD would be more likely to undergo cross type double stenting. EUS-BD may be more suitable as an initial drainage method in patients requiring stenting for duodenal stenosis in the second portion or in those patients needing a gastroduodenal stent covering the papilla. EUS-BD has shown utility in patients with previously placed gastroduodenal stents (11) . Regardless of EBD, however, some patients treated with the separate type of double stenting who experienced stent dysfunction nevertheless underwent successful re-intervention via the initial route, suggesting that the separate type of double stenting may therefore be more effective.
Based on the findings of the present study, when biliary stenosis and gastroduodenal stenosis occur at the same time, we recommend the separate type of endoscopic double stenting as follows: When a gastroduodenal stenosis occurs at the pylorus or first portion of the duodenum, gastroduodenal stenting should be performed first, followed by EBD, passing a scope through the gastroduodenal stent (if possible) or EUS-HGS. When gastroduodenal stenosis occurs at the second portion of the duodenum, then gastroduodenal stenting should be performed first, followed by EUS-CDS (if possible) or EUS-HGS. Finally, when gastroduodenal stenosis occurs at the third portion of the duodenum, then any possible biliary drainage technique should be performed first, followed by gastroduodenal stent placement (Fig. 4) .
Although none of these patients in this study were treated with a covered type gastroduodenal stent, re-intervention for biliary stent dysfunction tended to be extremely difficult in the cross type group. The use of covered type gastroduodenal stents (34) complicates re-intervention and increases the demand for separate type double stenting. More of our patients underwent EUS-CDS than EUS-HGS. Although double stenting with EUS-HGS is almost certainly the separate type when it is performed, this method is complicated, requires advanced techniques, and is reportedly associated with a high frequency (19-30%) of slightly serious complications (14) (15) (16) (19) (20) (21) . EUS-HGS has become increasingly popular in recent years; notably, however, this technique is still in the developmental stages, and its indications should therefore be limited to patients in good condition or with a long expected survival time. Because of the retrospective nature of this study, there were no uniform standards for the re-intervention method; thus, some patients who underwent PTBD could also have undergone EUS-BD. Further studies are needed to establish the usability of EUS-BD for reintervention.
In conclusion, the separate type of double stenting may contribute to successful biliary re-intervention due to stent dysfunction and thereby maintain the initial drainage route longer. The biliary drainage outcomes should thus be considered when choosing the type of double stenting.
The authors state that they have no Conflict of Interest (COI).
Financial Support
This study was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan (23-011).
